May 8, 2018 / 2:47 AM / in 6 months

BRIEF-Janssen Announces Darzalex U.S. FDA Approval For Patients With Multiple Myeloma

May 7 (Reuters) -

* JANSSEN ANNOUNCES DARZALEX® (DARATUMUMAB) U.S. FDA APPROVAL FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE

* JANSSEN PHARMA - FDA APPROVAL OF DARZALEX IN COMBINATION WITH BORTEZOMIB, MELPHALAN AND PREDNISONE MARKS ITS FIFTH INDICATION IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below